A widening spread between WAC and ASP is consistent with at least four distinct mechanisms: increasing PBM rebates for formulary placement, growing 340B purchasing volume, Medicaid best price adjustments, and changes in the channel mix of sales between Part B physician-administered and Part D retail channels. Each mechanism has different implications for manufacturer margins, payer economics, and competitive positioning. The cross-benchmark data reveals that the spread is widening. It does not, by itself, identify which mechanism is responsible. That ambiguity is not a flaw in the analytical approach—it is the fundamental epistemological challenge of interpreting indirect pricing signals in an opaque market.
The Attribution Problem
ASP is calculated by manufacturers and reported to CMS. The calculation methodology requires manufacturers to exclude from the ASP calculation sales subject to nominal pricing (essentially free goods), but otherwise includes most price concessions in the net price figure. The result is a number that reflects the combined effect of all gross-to-net mechanisms without distinguishing between them.
A manufacturer’s reported gross-to-net in an earnings call is itself an aggregate—’approximately 55% of list’—without channel or mechanism decomposition. The analyst looking at MedPricer’s WAC-ASP spread is seeing the same aggregate, expressed differently. The spread is not more or less informative than the earnings disclosure about what is driving gross-to-net; it is a different representation of the same opacity.
When Multiple Mechanisms Move Simultaneously
The attribution problem becomes particularly acute when multiple gross-to-net mechanisms are moving in the same direction simultaneously—which often happens because they are correlated. Formulary cycle negotiations, which drive PBM rebate changes, often occur at the same time as Medicaid rebate recalculations, because both are triggered by similar calendar events. When a manufacturer faces simultaneous pressure across multiple channels, the WAC-ASP spread may widen faster than any single mechanism would produce, without any single mechanism being identifiable as the dominant driver.
For an investor attempting to model which contracts or channels are producing the gross-to-net pressure, this simultaneous movement is a genuine analytical obstacle. MedPricer’s data can confirm that the spread widened and track its trajectory. It cannot decompose the contributors without additional drug-specific and channel-specific information.
The Value of Ruling Out Explanations
Even when cross-benchmark data cannot definitively attribute a pricing signal to a specific mechanism, it can rule out certain explanations. If WAC is rising while ASP is stable, the spread widening cannot be attributed to list price deflation—by definition, list price is increasing. If NADAC is rising for a drug with no known supply constraints, the increase is more likely to reflect manufacturer pricing decisions than acquisition cost pass-through from supply disruption.
This process of elimination—ruling out explanations that are inconsistent with the observed data pattern—is where cross-benchmark analysis provides its most reliable value. The analytical result is not a confident attribution but a narrowed range of plausible interpretations, which is precisely what rigorous analysis of ambiguous signals should produce.
Designing for Uncertainty
MedPricer’s product architecture should, ideally, be designed to communicate interpretive uncertainty alongside the signal data. A dashboard that displays WAC-ASP spread trends without flagging the range of mechanisms that could produce the observed pattern would be accurate in its data presentation but misleading in its implied interpretive confidence. The most analytically honest version of this product presents the signal, acknowledges the attribution ambiguity, and provides the contextual information—therapeutic category, competitive dynamics, known policy events—that allows users to make drug-specific attribution judgments.
That design philosophy is harder to execute than a confident-looking dashboard, and it requires users who are comfortable operating under uncertainty. For hedge fund analysts and policy researchers with genuine expertise, that is the right design. For less sophisticated users who want clean answers, the interpretive complexity is a usability challenge that no amount of interface design can fully resolve.
